1. P436 Efficacy and safety of biosimilars of anti-TNF-a in paediatric-onset Inflammatory Bowel Disease: Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD). (21st January 2022) Authors: Dipasquale, V; Pellegrino, S; Cucinotta, U; Citrano, M; Graziano, F; Cappello, M; Busacca, A; Orlando, A; Accomando, S; Romano, C Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i419 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P436 SPOSAB ABP 501 - A Sicilian Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Adalimumab Biosimilar ABP 501. (27th May 2021) Authors: Macaluso, F; Cappello, M; Busacca, A; Fries, W; Viola, A; Costantino, G; Magnano, A; Vinci, E; Ferracane, C; Privitera, A C; Piccillo, G; Belluardo, N; Giangreco, E; Romano, C; Citrano, M; Graziano, F; Garufi, S; Bertolami, C; Scrivo, B; Renna, S Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S437 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗